Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Rifomycin S
2. Rifampicin S
Molecular Weight | 822.9 g/mol |
---|---|
Molecular Formula | C43H58N4O12 |
XLogP3 | 4 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 5 |
Exact Mass | 822.40512330 g/mol |
Monoisotopic Mass | 822.40512330 g/mol |
Topological Polar Surface Area | 217 A^2 |
Heavy Atom Count | 59 |
Formal Charge | 0 |
Complexity | 1750 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 4 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Rifadin |
PubMed Health | Rifampin (Injection) |
Drug Classes | Antitubercular |
Drug Label | RIFADIN (rifampin capsules USP) for oral administration contain 150 mg or 300 mg rifampin per capsule. The 150 mg and 300 mg capsules also contain, as inactive ingredients: corn starch, D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin |
Active Ingredient | Rifampin |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | 150mg; 300mg; 600mg/vial |
Market Status | Prescription |
Company | Sanofi Aventis Us |
2 of 6 | |
---|---|
Drug Name | Rifampin |
Active Ingredient | Rifampin |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | 150mg; 300mg; 600mg/vial |
Market Status | Prescription |
Company | Bedford; Lupin Pharms; Sandoz; Emcure Pharms; Fresenius Kabi Usa; Versapharm; Lannett; Agila Speclts |
3 of 6 | |
---|---|
Drug Name | Rimactane |
PubMed Health | Rifampin |
Drug Classes | Antitubercular |
Drug Label | Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, soluble in ethyl acetate and in methanol. Its molecular weight i... |
Active Ingredient | Rifampin |
Dosage Form | Capsule |
Route | Oral |
Strength | 300mg |
Market Status | Prescription |
Company | Prosam Labs |
4 of 6 | |
---|---|
Drug Name | Rifadin |
PubMed Health | Rifampin (Injection) |
Drug Classes | Antitubercular |
Drug Label | RIFADIN (rifampin capsules USP) for oral administration contain 150 mg or 300 mg rifampin per capsule. The 150 mg and 300 mg capsules also contain, as inactive ingredients: corn starch, D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin |
Active Ingredient | Rifampin |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | 150mg; 300mg; 600mg/vial |
Market Status | Prescription |
Company | Sanofi Aventis Us |
5 of 6 | |
---|---|
Drug Name | Rifampin |
Active Ingredient | Rifampin |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | 150mg; 300mg; 600mg/vial |
Market Status | Prescription |
Company | Bedford; Lupin Pharms; Sandoz; Emcure Pharms; Fresenius Kabi Usa; Versapharm; Lannett; Agila Speclts |
6 of 6 | |
---|---|
Drug Name | Rimactane |
PubMed Health | Rifampin |
Drug Classes | Antitubercular |
Drug Label | Rifampin is a semisynthetic antibiotic derivative of rifamycin SV. Rifampin is a red-brown crystalline powder very slightly soluble in water at neutral pH, freely soluble in chloroform, soluble in ethyl acetate and in methanol. Its molecular weight i... |
Active Ingredient | Rifampin |
Dosage Form | Capsule |
Route | Oral |
Strength | 300mg |
Market Status | Prescription |
Company | Prosam Labs |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-12
Pay. Date : 2013-01-22
DMF Number : 13383
Submission : 1998-09-01
Status : Active
Type : II
Registration Number : 218MF10388
Registrant's Address : Via Angelo Titi, 22/26, Zona ex punto franco, 72100 Brindisi, Italy
Initial Date of Registration : 2006-03-20
Latest Date of Registration :
NDC Package Code : 82297-101
Start Marketing Date : 1973-04-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Certificate Number : R0-CEP 2000-337 - Rev 03
Issue Date : 2005-02-18
Type : TSE
Substance Number : 52
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13214
Submission : 1998-04-30
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-09-10
Written Confirmation Number : WC-0201
Address of the Firm :
NDC Package Code : 57297-444
Start Marketing Date : 1998-04-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2009-10-27
Registration Number : 20091027-103-F-48-03
Manufacturer Name : Lupin Limited,
Manufacturer Address : India, T-142, MIDC, Tarapur, Via Boisar, Maharashtra 401 506
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-04
Pay. Date : 2013-09-26
DMF Number : 13663
Submission : 1998-09-01
Status : Active
Type : II
NDC Package Code : 52972-0026
Start Marketing Date : 1998-11-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Chong Kun Dang Bio Co., Ltd.
Registration Date : 2009-01-30
Registration Number : 20090130-103-F-36-01
Manufacturer Name : Chong Kun Dang Bio Co., Ltd._x000D_
Manufacturer Address : 454,486 Biblock 16 Complex, Moknae-dong, Danwon-gu, Ansan-si, Gyeonggi-do (425-100) (368-3, Chungjeong-ro 3-ga, Seodaemun-gu, Seoul (120-756))
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13796
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : CEP 2009-275 - Rev 05
Issue Date : 2024-05-27
Type : Chemical
Substance Number : 52
Status : Valid
NDC Package Code : 73005-0006
Start Marketing Date : 2022-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-05-13
Pay. Date : 2022-03-29
DMF Number : 36879
Submission : 2022-04-04
Status : Active
Type : II
NDC Package Code : 17337-0031
Start Marketing Date : 2012-12-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38768
Submission : 2023-09-29
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13398
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13644
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13717
Submission : 1998-09-01
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
98
PharmaCompass offers a list of Rifampin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rifampin manufacturer or Rifampin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifampin manufacturer or Rifampin supplier.
PharmaCompass also assists you with knowing the Rifampin API Price utilized in the formulation of products. Rifampin API Price is not always fixed or binding as the Rifampin Price is obtained through a variety of data sources. The Rifampin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rifampicina [INN-Spanish] manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rifampicina [INN-Spanish], including repackagers and relabelers. The FDA regulates Rifampicina [INN-Spanish] manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rifampicina [INN-Spanish] API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rifampicina [INN-Spanish] manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rifampicina [INN-Spanish] supplier is an individual or a company that provides Rifampicina [INN-Spanish] active pharmaceutical ingredient (API) or Rifampicina [INN-Spanish] finished formulations upon request. The Rifampicina [INN-Spanish] suppliers may include Rifampicina [INN-Spanish] API manufacturers, exporters, distributors and traders.
click here to find a list of Rifampicina [INN-Spanish] suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rifampicina [INN-Spanish] DMF (Drug Master File) is a document detailing the whole manufacturing process of Rifampicina [INN-Spanish] active pharmaceutical ingredient (API) in detail. Different forms of Rifampicina [INN-Spanish] DMFs exist exist since differing nations have different regulations, such as Rifampicina [INN-Spanish] USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rifampicina [INN-Spanish] DMF submitted to regulatory agencies in the US is known as a USDMF. Rifampicina [INN-Spanish] USDMF includes data on Rifampicina [INN-Spanish]'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rifampicina [INN-Spanish] USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rifampicina [INN-Spanish] suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rifampicina [INN-Spanish] Drug Master File in Japan (Rifampicina [INN-Spanish] JDMF) empowers Rifampicina [INN-Spanish] API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rifampicina [INN-Spanish] JDMF during the approval evaluation for pharmaceutical products. At the time of Rifampicina [INN-Spanish] JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rifampicina [INN-Spanish] suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rifampicina [INN-Spanish] Drug Master File in Korea (Rifampicina [INN-Spanish] KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rifampicina [INN-Spanish]. The MFDS reviews the Rifampicina [INN-Spanish] KDMF as part of the drug registration process and uses the information provided in the Rifampicina [INN-Spanish] KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rifampicina [INN-Spanish] KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rifampicina [INN-Spanish] API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rifampicina [INN-Spanish] suppliers with KDMF on PharmaCompass.
A Rifampicina [INN-Spanish] CEP of the European Pharmacopoeia monograph is often referred to as a Rifampicina [INN-Spanish] Certificate of Suitability (COS). The purpose of a Rifampicina [INN-Spanish] CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Rifampicina [INN-Spanish] EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Rifampicina [INN-Spanish] to their clients by showing that a Rifampicina [INN-Spanish] CEP has been issued for it. The manufacturer submits a Rifampicina [INN-Spanish] CEP (COS) as part of the market authorization procedure, and it takes on the role of a Rifampicina [INN-Spanish] CEP holder for the record. Additionally, the data presented in the Rifampicina [INN-Spanish] CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Rifampicina [INN-Spanish] DMF.
A Rifampicina [INN-Spanish] CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Rifampicina [INN-Spanish] CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Rifampicina [INN-Spanish] suppliers with CEP (COS) on PharmaCompass.
A Rifampicina [INN-Spanish] written confirmation (Rifampicina [INN-Spanish] WC) is an official document issued by a regulatory agency to a Rifampicina [INN-Spanish] manufacturer, verifying that the manufacturing facility of a Rifampicina [INN-Spanish] active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rifampicina [INN-Spanish] APIs or Rifampicina [INN-Spanish] finished pharmaceutical products to another nation, regulatory agencies frequently require a Rifampicina [INN-Spanish] WC (written confirmation) as part of the regulatory process.
click here to find a list of Rifampicina [INN-Spanish] suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rifampicina [INN-Spanish] as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rifampicina [INN-Spanish] API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rifampicina [INN-Spanish] as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rifampicina [INN-Spanish] and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rifampicina [INN-Spanish] NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rifampicina [INN-Spanish] suppliers with NDC on PharmaCompass.
Rifampicina [INN-Spanish] Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rifampicina [INN-Spanish] GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rifampicina [INN-Spanish] GMP manufacturer or Rifampicina [INN-Spanish] GMP API supplier for your needs.
A Rifampicina [INN-Spanish] CoA (Certificate of Analysis) is a formal document that attests to Rifampicina [INN-Spanish]'s compliance with Rifampicina [INN-Spanish] specifications and serves as a tool for batch-level quality control.
Rifampicina [INN-Spanish] CoA mostly includes findings from lab analyses of a specific batch. For each Rifampicina [INN-Spanish] CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rifampicina [INN-Spanish] may be tested according to a variety of international standards, such as European Pharmacopoeia (Rifampicina [INN-Spanish] EP), Rifampicina [INN-Spanish] JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rifampicina [INN-Spanish] USP).